Withdrawal interference scale: a novel measure of withdrawal-related life disruption in opioid use disorder and alcohol use disorder.

IF 2.7 3区 医学 Q2 PSYCHOLOGY, CLINICAL
Orman Trent Hall, Tommy Gunawan, Julie Teater, Craig Bryan, Stephanie Gorka, Vijay A Ramchandani
{"title":"Withdrawal interference scale: a novel measure of withdrawal-related life disruption in opioid use disorder and alcohol use disorder.","authors":"Orman Trent Hall, Tommy Gunawan, Julie Teater, Craig Bryan, Stephanie Gorka, Vijay A Ramchandani","doi":"10.1080/00952990.2024.2350057","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background:</i> <i>Hyperkatifeia</i> describes amplified emotional and motivational withdrawal due to addiction-related sensitization of brain-stress-systems. Hyperkatifeia has been proposed as a target for addiction treatment development. However, translation of basic research in this area will require new tools designed to measure <i>hyperkatifeia</i> and related phenomena outside of laboratory settings.<i>Objectives:</i> We define a novel concept, <i>withdrawal interference</i>, and introduce a new tool - the <i>Withdrawal Interference Scale</i> (WIS) - which measures the impact of withdrawal on daily life among individuals with OUD or AUD.<i>Methods:</i> Described are the combined results of three separate cross-sectional studies. The structural validity, convergent validity, construct validity, trans-diagnostic (AUD/OUD) configural, metric, and scalar invariance, internal consistency, and composite reliability of WIS was tested among three independent samples of 1) treatment-seeking adults with OUD (<i>n</i> = 132), 2) treatment-seeking adults with AUD (<i>n</i> = 123), and 3) non-treatment-seeking adults with OUD (<i>n</i> = 140). Males numbered 218 and females were 163.<i>Results:</i> WIS exhibited structural validity (1 factor), convergent validity (average variance extracted .670-.676), construct validity, trans-diagnostic configural (χ2/df = 2.10), metric (Δχ2 = 5.70, <i>p</i> = .681), and scalar invariance (Δχ2 = 12.34, <i>p</i> = .338), internal consistency (α .882-928), and composite reliability (.924-.925).<i>Conclusion:</i> These results suggest WIS is a valid and reliable instrument for measuring withdrawal-related life disruption in AUD and OUD. Further, given our findings of transdiagnostic measurement invariance, WIS scores of individuals with AUD and OUD can be meaningfully compared in future statistical analyses.</p>","PeriodicalId":48957,"journal":{"name":"American Journal of Drug and Alcohol Abuse","volume":" ","pages":"1-13"},"PeriodicalIF":2.7000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Drug and Alcohol Abuse","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00952990.2024.2350057","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hyperkatifeia describes amplified emotional and motivational withdrawal due to addiction-related sensitization of brain-stress-systems. Hyperkatifeia has been proposed as a target for addiction treatment development. However, translation of basic research in this area will require new tools designed to measure hyperkatifeia and related phenomena outside of laboratory settings.Objectives: We define a novel concept, withdrawal interference, and introduce a new tool - the Withdrawal Interference Scale (WIS) - which measures the impact of withdrawal on daily life among individuals with OUD or AUD.Methods: Described are the combined results of three separate cross-sectional studies. The structural validity, convergent validity, construct validity, trans-diagnostic (AUD/OUD) configural, metric, and scalar invariance, internal consistency, and composite reliability of WIS was tested among three independent samples of 1) treatment-seeking adults with OUD (n = 132), 2) treatment-seeking adults with AUD (n = 123), and 3) non-treatment-seeking adults with OUD (n = 140). Males numbered 218 and females were 163.Results: WIS exhibited structural validity (1 factor), convergent validity (average variance extracted .670-.676), construct validity, trans-diagnostic configural (χ2/df = 2.10), metric (Δχ2 = 5.70, p = .681), and scalar invariance (Δχ2 = 12.34, p = .338), internal consistency (α .882-928), and composite reliability (.924-.925).Conclusion: These results suggest WIS is a valid and reliable instrument for measuring withdrawal-related life disruption in AUD and OUD. Further, given our findings of transdiagnostic measurement invariance, WIS scores of individuals with AUD and OUD can be meaningfully compared in future statistical analyses.

戒断干扰量表:阿片类药物使用障碍和酒精使用障碍患者戒断相关生活干扰的新型测量方法。
背景:过度戒断(Hyperkatifeia)描述的是由于与成瘾相关的大脑应激系统敏感化而导致的情绪和动机戒断。有人建议将超激戒断作为成瘾治疗发展的目标。然而,要将这一领域的基础研究成果转化为现实,就需要设计新的工具,以便在实验室环境之外测量过度戒断和相关现象:我们定义了一个新概念--戒断干扰,并引入了一种新工具--戒断干扰量表(WIS),用于测量戒断对 OUD 或 AUD 患者日常生活的影响:方法:描述了三项独立横断面研究的综合结果。在三个独立样本中测试了WIS的结构效度、收敛效度、构造效度、跨诊断(AUD/OUD)配置效度、度量效度和标度不变性、内部一致性和综合信度,这三个独立样本分别是:1)寻求治疗的成人OUD患者(n = 132);2)寻求治疗的成人AUD患者(n = 123);3)未寻求治疗的成人OUD患者(n = 140)。男性 218 人,女性 163 人:结果显示:WIS 具有结构效度(1 个因子)、收敛效度(平均方差提取率 .670-.676)、建构效度、跨诊断配置效度(χ2/df = 2.10)、度量(Δχ2 = 5.70,p = .681)和标度不变性(Δχ2 = 12.34,p = .338)、内部一致性(α .882-928)和综合信度(.924-.925):这些结果表明,WIS 是一种有效且可靠的工具,可用于测量 AUD 和 OUD 中与戒断相关的生活干扰。此外,鉴于我们发现的跨诊断测量不变量,在未来的统计分析中,可以对AUD和OUD患者的WIS得分进行有意义的比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
3.70%
发文量
68
期刊介绍: The American Journal of Drug and Alcohol Abuse (AJDAA) is an international journal published six times per year and provides an important and stimulating venue for the exchange of ideas between the researchers working in diverse areas, including public policy, epidemiology, neurobiology, and the treatment of addictive disorders. AJDAA includes a wide range of translational research, covering preclinical and clinical aspects of the field. AJDAA covers these topics with focused data presentations and authoritative reviews of timely developments in our field. Manuscripts exploring addictions other than substance use disorders are encouraged. Reviews and Perspectives of emerging fields are given priority consideration. Areas of particular interest include: public health policy; novel research methodologies; human and animal pharmacology; human translational studies, including neuroimaging; pharmacological and behavioral treatments; new modalities of care; molecular and family genetic studies; medicinal use of substances traditionally considered substances of abuse.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信